Cargando…
Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504141/ https://www.ncbi.nlm.nih.gov/pubmed/34363742 http://dx.doi.org/10.1002/cac2.12206 |
| _version_ | 1784581271459987456 |
|---|---|
| author | Huang, Jiwei Wang, Yueming Zhang, Haoran Hu, Xiaoyi Wang, Ping Cai, Wen Yuan, Yichu Zeng, Hao Zhang, Jin Kong, Wen Huang, Yiran Wang, Shuo Guo, Jianming Wei, Qiang Xue, Wei |
| author_facet | Huang, Jiwei Wang, Yueming Zhang, Haoran Hu, Xiaoyi Wang, Ping Cai, Wen Yuan, Yichu Zeng, Hao Zhang, Jin Kong, Wen Huang, Yiran Wang, Shuo Guo, Jianming Wei, Qiang Xue, Wei |
| author_sort | Huang, Jiwei |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8504141 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85041412021-10-18 Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody Huang, Jiwei Wang, Yueming Zhang, Haoran Hu, Xiaoyi Wang, Ping Cai, Wen Yuan, Yichu Zeng, Hao Zhang, Jin Kong, Wen Huang, Yiran Wang, Shuo Guo, Jianming Wei, Qiang Xue, Wei Cancer Commun (Lond) Letters to the Editor John Wiley and Sons Inc. 2021-08-07 /pmc/articles/PMC8504141/ /pubmed/34363742 http://dx.doi.org/10.1002/cac2.12206 Text en © 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat‐sen University Cancer Center https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| spellingShingle | Letters to the Editor Huang, Jiwei Wang, Yueming Zhang, Haoran Hu, Xiaoyi Wang, Ping Cai, Wen Yuan, Yichu Zeng, Hao Zhang, Jin Kong, Wen Huang, Yiran Wang, Shuo Guo, Jianming Wei, Qiang Xue, Wei Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody |
| title | Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody |
| title_full | Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody |
| title_fullStr | Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody |
| title_full_unstemmed | Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody |
| title_short | Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody |
| title_sort | clinical outcomes of second‐line treatment following first‐line vegfr‐tki failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐pd‐1 antibody |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504141/ https://www.ncbi.nlm.nih.gov/pubmed/34363742 http://dx.doi.org/10.1002/cac2.12206 |
| work_keys_str_mv | AT huangjiwei clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT wangyueming clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT zhanghaoran clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT huxiaoyi clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT wangping clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT caiwen clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT yuanyichu clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT zenghao clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT zhangjin clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT kongwen clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT huangyiran clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT wangshuo clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT guojianming clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT weiqiang clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody AT xuewei clinicaloutcomesofsecondlinetreatmentfollowingfirstlinevegfrtkifailureinpatientswithmetastaticrenalcellcarcinomaacomparisonofaxitinibaloneandaxitinibplusantipd1antibody |